Nintedanib Esylate Inhalation Powder(Cspc)

乙磺酸尼达尼布吸入粉雾剂（石药集团）

Report date: 2026/02/13 20:01:31
First In Class

Base Information

Drug NameNintedanib Esylate Inhalation Powder(Cspc)
Drug Alias NameIntedanib宁替达尼nintedanib宁特达尼nintedanibum +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[10] 
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 3Platelet-derived growth factor receptor beta +[10] 
Therapy Area/IndicationsIdiopathic Pulmonary FibrosisPulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCspc-Nbp Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Kangchuanglian Biopharmaceutical Technology Research Co LtdCspc-Nbp Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary FibrosisPulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG